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Background: The presence of myocardial fibrosis is associated with worse clinical outcomes in hypertrophic
cardiomyopathy (HCM). Cardiovascular magnetic resonance (CMR) with late gadolinium enhancement (LGE)
sequences can detect regional, but not diffuse myocardial fibrosis. Post-contrast T1 mapping is an emerging CMR
technique that may enable the non-invasive evaluation of diffuse myocardial fibrosis in HCM. The purpose of this
study was to non-invasively detect and quantify diffuse myocardial fibrosis in HCM with CMR and examine its
relationship to diastolic performance.
Methods: We performed CMR on 76 patients - 51 with asymmetric septal hypertrophy due to HCM and 25 healthy
controls. Left ventricular (LV) morphology, function and distribution of regional myocardial fibrosis were evaluated
with cine imaging and LGE. A CMR T1 mapping sequence determined the post-contrast myocardial T1 time as an
index of diffuse myocardial fibrosis. Diastolic function was assessed by transthoracic echocardiography.
Results: Regional myocardial fibrosis was observed in 84% of the HCM group. Post-contrast myocardial T1 time was
significantly shorter in patients with HCM compared to controls, consistent with diffuse myocardial fibrosis (498 ±
80 ms vs. 561 ± 47 ms, p < 0.001). In HCM patients, post-contrast myocardial T1 time correlated with mean E/e’
(r = −0.48, p < 0.001).
Conclusions: Patients with HCM have shorter post-contrast myocardial T1 times, consistent with diffuse myocardial
fibrosis, which correlate with estimated LV filling pressure, suggesting a mechanistic link between diffuse myocardial
fibrosis and abnormal diastolic function in HCM.
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Hypertrophic cardiomyopathy (HCM) is a relatively
common inherited cardiac disease defined by the pres-
ence of otherwise unexplained left ventricular (LV)
hypertrophy associated with non-dilated ventricular
chambers [1,2]. Inheritance is autosomal dominant and* Correspondence: Andrew.Taylor@bakeridi.edu.au
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reproduction in any medium, provided the ormutations generally involve sarcomeric genes [3,4].
Patients may develop symptoms from LV outflow tract
(LVOT) obstruction [2] and, in the presence of certain
high-risk features, an implantable cardioverter defibrilla-
tor is recommended to reduce the risk of sudden cardiac
death [5]. Many patients, however, develop symptoms of
breathlessness due to diastolic dysfunction which is
largely independent of the severity of LVOT obstruction
[6]. As patients with HCM are known to develop diffuse,
as well as regional myocardial fibrosis, this maytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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leading to impaired diastolic filling [7].
Cardiovascular magnetic resonance (CMR) after intra-
venous administration of gadolinium contrast can non-
invasively characterize myocardial tissue [8]. Late gado-
linium enhancement (LGE) in HCM patients represents
replacement fibrosis histologically [9,10] and portends a
worse outcome [11]. LGE has been noted in up to 80%
of HCM patients [12-14], typically within the thickened
interventricular septum or at points of insertion of the
RV free wall [15,16]. Histologic evaluation of myocardial
tissue in HCM, however, has demonstrated a more
global, or diffuse, increase in fibrosis that cannot be
detected by standard CMR LGE sequences [7,10].
Post-contrast myocardial longitudinal relaxation time
(T1) mapping is an emerging CMR technique that can
detect and quantify diffuse interstitial myocardial fibrosis
[17] without the necessity for invasive biopsy. Different
T1 mapping protocols have identified diffuse myocardial
fibrosis in several cardiac disease states [8,18], however
research involving HCM is limited [19,20].
A comprehensive non-invasive evaluation of regional
and diffuse myocardial fibrosis in a typical cohort of
HCM patients has not previously been described. This
study was undertaken to detect and quantify diffuse
myocardial fibrosis in these patients using a histologically-
validated CMR post-contrast myocardial T1 mapping tech-
nique [17]. Furthermore, we investigated the relationships




All research was performed at the Alfred Hospital,
Melbourne, Australia between August 2010 and October
2011. Fifty-one consecutive patients (39 men, 12 women)
referred to our CMR department for the further evalu-
ation of asymmetric septal hypertrophy (ASH) due to
HCM were invited to participate. ASH was defined as an
interventricular septum thickness of ≥15 mm with a ratio
of septal-to-lateral ventricular wall thickness of ≥1.3:1.0 as
measured by echocardiography, and the diagnosis of
HCM required the absence of another condition that
could cause the degree of hypertrophy observed [1].
Twenty-five asymptomatic subjects with no documented
history of cardiovascular disease formed a healthy control
group.
Exclusion criteria included previous septal reduction
therapy; previously documented coronary artery disease
or current symptoms suggestive of coronary artery
disease; atrial fibrillation; diabetes mellitus; contraindica-
tions to CMR, including pacemaker and defibrillator im-
plantation; and significant renal dysfunction (estimated
glomerular filtration rate (eGFR) <30 mL/min/1.73m2).Informed consent was obtained from all participants
and the study was conducted in accordance with the
Alfred Hospital Ethics Committee’s guidelines.
CMR protocol
CMR sequences
We performed CMR using a clinical 1.5-T scanner
(Signa HD 1.5-T, GE Healthcare, Waukesha, Wisconsin,
USA). All sequences were acquired during a breath-hold
of 10–15 s. LV function was assessed by a steady-state
free precession (SSFP) pulse sequence (repetition time
[TR] = 3.8 ms, echo time [TE] = 1.6 ms, 30 phases, slice
thickness 8 mm).
Initial cine CMR sequences were performed in 3
standard long-axis (4-, 3- and 2-chamber views) and
short-axis slices (basal, mid, and apical), kept identical
for each subsequent sequence throughout the CMR
examination [21]. From an end-diastolic, 4-chamber,
long-axis view, 5 equally spaced short-axis slices were
planned, so that the 2 outer slices lined up exactly either
with the tip of the apex or the mitral annulus. The 2
outer slices were then deleted, leaving 3 slices corre-
sponding to typical basal, mid, and apical short-axis
views. To calculate LV volume and function, a contigu-
ous short-axis SSFP stack was acquired (8 mm slice
thickness, no gap), extending from the mitral valve an-
nulus to the LV apex.
LGE was evaluated 10 min after a bolus of
gadolinium-diethylene triamine penta-acetic acid (DTPA)
(0.2 mmol/kg BW Magnevist, Schering, Germany) to iden-
tify regional fibrosis using a T1-weighted inversion recovery
gradient echo technique (TR 7.1 ms, TE 3.1 ms, inversion
time [TI] individually determined to null the myocardial
signal, slice thickness 8 mm, matrix 256 × 192, number of
acquisitions = 2). The TI optimization sequence was per-
formed 8 min post-gadolinium administration and was a
fast gradient echo, inversion recovery, gated, multi-phase
acquisition, commencing at an inversion time of 150 ms
and increasing in 25 ms increments to 250 ms, in a single
mid-ventricular short-axis slice. A visual determination of
the optimum TI to null the myocardial signal was then
made. LGE imaging was performed using both standard
long-axis and short-axis views of the LV (including a con-
tiguous stack of slices from the mitral valve annulus to the
apex).
For the evaluation of diffuse myocardial fibrosis, a T1
mapping sequence was used to cycle through acquisition
of images obtained at the 3 standard short-axis levels
over a range of inversion times [17]. The sequence con-
sisted of an electrocardiogram-triggered, inversion-
recovery prepared, 2-dimensional fast gradient echo se-
quence employing variable temporal sampling of -space
(VAST) [22] (Global Applied Science Laboratory, GE
Healthcare). Ten images were acquired sequentially at
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20 min after the bolus of gadolinium-DTPA and over a
series of 3 to 5 breath-holds. Imaging parameters were
TR/TE: 3.7 ms/1.2 ms, flip angle: 20°, 256×128 acquisi-
tion matrix, 36 × 27 cm field of view, slice thickness 8
mm, TI: 75–750 ms, trigger delay 300 ms, and views per
segment = 24. The acquisition of all ten images for each
myocardial slice was completed in approximately three
minutes. These images were then processed with a curve
fitting technique to generate T1 maps.
Evaluation of LV dimensions, function, mass and regional
fibrosis
Volumetric analysis of the LV was performed using the
summation of disc method. Regional fibrosis was identi-
fied by LGE within the myocardium, defined quantita-
tively by a myocardial post-contrast signal intensity 6 SD
above that within a reference region of remote myocar-
dium (without LGE) within the same slice [23]. LGE was
defined as being present only if it was identified in two
orthogonal views.
Evaluation of diffuse fibrosis with T1 mapping
Following image acquisition, the ten short-axis images of
varying inversion times were transferred to an external
computer for analysis using a dedicated research soft-
ware package (Cinetool, Global Applied Science Labora-
tory, GE Healthcare). This provided the ability to
analyze regions of interest (ROIs) to find average T1 for
that area, as well as a pixel-by-pixel determination of T1,
by fitting data acquired at various preparation times to
the exponential curve: Mz (t = TI) = M0(A – B[e
-t/T1=]),
relating the sample magnetization Mz observed at the
time t = TI to the equilibrium magnetization M0 and
sample T1, where TI denotes inversion time for an inver-
sion recovery experiment. For each short-axis image,
a ROI was drawn around the entire LV myocardium
(excluding papillary muscles) to calculate post-contrastFigure 1 Calculation of post-contrast myocardial T1 time in HCM. (A)
asymmetric septal hypertrophy due to HCM. (B) Post-contrast T1 mapping
chosen to include LV myocardium, but exclude a region of late gadoliniummyocardial T1 time. In subjects with regional fibrosis
detected by LGE, these regions were excluded from the
ROI for the primary analysis of post-contrast myocardial
T1 time (see Figure 1). To investigate for regional varia-
tions in T1 time, separate ROIs were drawn around
hypertrophied (defined as CMR-measured wall thickness
≥ 11 mm during diastole) and non-hypertrophied LV
myocardium for each short-axis slice.
Evaluation of diastolic function
Transthoracic echocardiography with a standard clinical
protocol was performed on all patients immediately
prior to CMR. Diastolic function was assessed by a com-
bination of mitral inflow pattern (E to A ratio and decel-
eration time) and mitral annular velocities (e’, measured
at the septal and lateral aspects of the mitral annulus in
the apical 4-chamber view). Additionally, mitral E/e’
(septal, lateral and mean) was chosen as an index of LV
filling pressure.
Image analysis
All CMR and echocardiogram images were interpreted
by two experienced readers unaware of the subjects’ clin-
ical information and the results of other diagnostic tests.
Endocardial and epicardial LV contours were drawn
manually for each diastolic and systolic frame, excluding
papillary muscles.
Statistical methods
All data are expressed as mean ± SD unless otherwise
indicated. Comparison of continuous variables utilized
unpaired Student t-test. Comparisons of proportions
were made with chi-squared analysis. Multiple compari-
sons were performed by analysis of variance (ANOVA),
with post hoc testing (Holm-Sidak method) as appropri-
ate. Correlations of variables were determined by calcu-
lating the Pearson Product Moment. Multiple linear
regression was used to determine the independence ofShort-axis steady-state free precession image of a patient with
image at the same short-axis level, with the region of interest (shaded)
enhancement.
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all correlations with a p value < 0.1 entered into multiple
linear regression analysis. Binary categorical variables
were entered into the analyses using dummy coding.
Linear regression and Bland-Altman analysis were per-
formed to assess interobserver agreement. For all com-
parisons, a p value of < 0.05 was considered significant,
and all reported p values are 2-tailed. All analyses were
conducted using Stata software version 11.1 (StataCorp,
College Station, Texas).
Results
Clinical and demographic data
A total of 76 patients were evaluated during the study
period, comprising 51 patients with ASH due to HCM
and 25 control subjects. Baseline characteristics of both
groups are presented in Table 1. Patients in both groups
were of a similar age. 76% of HCM patients were male,
compared to 72% of control subjects. Body mass index
(BMI) was significantly higher in the HCM group (27.5
± 4.9 kg/m2 vs. 24.1 ± 2.7 kg/m2, p < 0.001). One-third
of HCM patients had a first-degree relative previously
diagnosed with HCM. 74% of patients reported symp-
toms attributable to HCM (including chest pain, dys-
pnoea, presyncope and/or syncope). The severity of
dyspnoea in HCM patients was generally mild, with no
patients experiencing New York Heart AssociationTable 1 Baseline characteristics
HCM (n=51) Control (n=25) p value
Age, y 48 ± 14 48 ± 17 0.8
Males, n (%) 39 (76%) 18 (72%) 0.7
Body mass index, kg/m2 27.5 ± 4.9 24.1 ± 2.7 <0.001




Chest pain 16 (31%) -
Dyspnoea 28 (55%) -
NYHA class I or II 51 (100%) -
Presyncope 18 (35%) -
Syncope 6 (12%) -
Medications, n (%)
Beta-blocker 29 (57%) -
Calcium channel blocker 10 (20%) -
Resting heart rate,
beats/min
60 ± 10 62 ± 9 0.6
Systolic blood pressure,
mm Hg
129 ± 16 133 ± 18 0.4
Hematocrit 0.43 ± 0.04 0.42 ± 0.03 0.3
eGFR, ml/min/1.73 m2 81 ± 12 86 ± 8 0.14
NYHA indicates New York Heart Association; and eGFR, estimated glomerular
filtration rate.(NYHA) class III/IV symptoms. Three-quarters of the
HCM group were receiving beta-blocker and/or non-
dihydropyridine calcium channel blocker therapy. There
were no significant differences in heart rate, systolic
blood pressure, hematocrit, or renal function between
the HCM and control groups.
CMR findings
CMR was successfully completed in all 76 patients and
the results are displayed in Table 2. The HCM group
had a significantly higher LV ejection fraction and a
greater LV mass indexed to body surface area (BSA)
compared to the control group. LV end-diastolic
volumes indexed to BSA were similar in both groups.
The maximum ventricular septal thickness of HCM
patients was 20 ± 3 mm compared to 8 ± 2 mm for con-
trol subjects, while the ratio of septal-to-lateral ventricu-
lar wall thickness for the HCM group was 2.3:1. LGE
was observed in 84% of HCM patients, generally loca-
lized to the ventricular septum or points of RV free wall
insertion. Subendocardially-based LGE, consistent with
ischemic scar, was not observed in any patient. The
mean quantity of LGE, expressed as a percentage of LV
mass, was 6.1 ± 7.7%.
Post-contrast myocardial T1 time in HCM and control
subject
The timing of acquisition of T1 mapping sequences after
the delivery of the gadolinium contrast bolus was similar
in both groups (23:43 ± 3:57 min vs. 22:34 ± 3:48 min,
p = 0.2). There was an excellent correlation between the
two blinded CMR specialist reviewers when they inde-
pendently calculated myocardial T1 times (r = 0.99,
p < 0.001). Bland-Altman analysis showed good inter-Table 2 Cardiac MRI data
HCM (n=51) Control (n=25) p value
LVEDV, ml 162 ± 36 156 ± 35 0.5
LVEDV indexed, ml/BSA 81 ± 14 83 ± 13 0.5
LVESV, ml 50 ± 17 63 ± 18 <0.01
LV stroke volume, ml 112 ± 27 94 ± 20 <0.01
LVEF, % 70 ± 7 60 ± 6 <0.001
LV mass, g 178 ± 54 98 ± 25 <0.001
LV mass indexed, g/BSA 89 ± 25 52 ± 9 <0.001
Septal thickness, mm 20 ± 3 8 ± 2 <0.001
Lateral wall thickness, mm 9 ± 2 8 ± 1 <0.05
Septal:lateral wall thickness 2.3 ± 0.7 1.1 ± 0.9 <0.001
Presence of LGE, n (%) 43 (84%) 0 (0%)
Quantity of LGE, % of
LV mass
6.1 ± 7.7 0
LVEDV indicates left ventricular end-diastolic volume; LVEF, left ventricular
ejection fraction; LVESV, left ventricular end-systolic volume; and LGE, late
gadolinium enhancement.
Table 4 Echocardiography data
HCM (n=51) Control (n=25) p value
Left atrial volume indexed,
ml/m2
51 ± 18 32 ± 10 <0.001
Resting LVOT gradient,
mm Hg
26 ± 36 4 ± 1 <0.001
Mitral E velocity, cm/s 0.8 ± 0.2 0.7 ± 0.2 0.1
Mitral A velocity, cm/s 0.6 ± 0.3 0.6 ± 0.2 0.5
E/A ratio 1.4 ± 0.6 1.4 ± 0.5 0.7
Deceleration time, ms 217 ± 51 188 ± 36 <0.01
Septal e’, cm/s 6.0 ± 1.7 8.8 ± 3.0 <0.001
Lateral e’, cm/s 8.3 ± 2.6 12.0 ± 4.0 <0.001
Mean e’, cm/s 7.1 ± 1.9 10.4 ± 3.3 <0.001
Septal E/e’ ratio 14.4 ± 5.8 8.9 ± 3.2 <0.001
Lateral E/e’ ratio 10.6 ± 4.7 6.4 ± 1.9 <0.001
Mean E/e’ ratio 12.5 ± 4.9 7.7 ± 2.4 <0.001
LVOT indicates left ventricular outflow tract.
Table 5 Predictors of post-contrast myocardial T1 time in
HCM group by simple and multiple linear regression
Simple linear regression Multiple linear regression
r p value β p value


















Diastolic blood 0.12 0.4
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0.29 ± 19.28 ms, limits of agreement were −38.29 to
38.84). Patients with HCM had significantly shorter
post-contrast myocardial T1 times compared with con-
trols (498 ± 80 ms vs. 561 ± 47 ms, p < 0.0001) (Table 3).
When regions of LGE were included in the analysis of
HCM patients, a further reduction in T1 time (483 ± 85
ms) was observed. Post-contrast T1 times were similar
in both hypertrophied and non-hypertrophied LV myo-
cardium (503 ± 127 ms vs. 497 ± 111 ms, p = 0.7). There
was no difference in post-contrast T1 times of the LV
blood pool between the HCM and control groups (304
± 31 ms vs. 306 ± 22 ms respectively, p = 0.8).
Echocardiography findings
Echocardiographic data are presented in Table 4. Left
atrial volume indexed to BSA was higher in the HCM
group. The mean resting LVOT gradient in HCM
patients was 26 ± 36 mm Hg. Septal, lateral, and mean
early diastolic mitral annular velocities (e’) as measured
by tissue Doppler imaging (TDI) were all lower in the
HCM group compared to controls, and septal, lateral,
and mean E/e’ were higher in the HCM group.
Correlates of post-contrast myocardial T1 time in HCM
patients
Significant negative correlations were observed between
post-contrast myocardial T1 time and age and BMI
(Table 5). Following multiple linear regression analysis,
the correlation between T1 time and age remained sig-
nificant. There were no associations between T1 time
and the presence of symptoms or NYHA class. There
were no significant correlations between T1 time and
resting heart rate, blood pressure, hematocrit or eGFR.
The presence and quantity of LGE (expressed as a per-
centage of LV mass) did not correlate with post-contrast
myocardial T1 time.
Correlates of diastolic dysfunction in HCM patients
Using mean E/e’ as a measure of diastolic dysfunction,
simple linear regression demonstrated significant posi-
tive correlations with age, indexed LV mass, maximum
septal thickness, indexed left atrial volume, and restingTable 3 Post-contrast myocardial T1 mapping data
HCM (n=51) Control (n=25) p value
Post-contrast T1 time, ms
LV myocardium, excluding LGE 498 ± 80 561 ± 47 <0.0001
LV myocardium, including LGE 483 ± 85 561 ± 47 <0.0001
LV blood pool 304 ± 31 306 ± 22 0.8
LGE indicates late gadolinium enhancement.LVOT gradient. A negative correlation was observed be-
tween mean E/e’ and post-contrast myocardial T1 time
(see Figure 2). No significant correlation was observed
between the amount of LGE and mean E/e’. In multi-
variate analysis, the correlation between mean E/e’ and









NYHA indicates New York Heart Association; eGFR, estimated glomerular
filtration rate; and LGE, late gadolinium enhancement.
Figure 2 Post-contrast myocardial T1 time and mean E/e’ in
HCM patients. A significant negative correlation was observed
between post-contrast myocardial T1 time and mean E/e’ (r = −0.48,
p < 0.001).
Table 6 Predictors of mean E/e’ in HCM group by simple
and multiple line regression
Simple linear regression Multiple linear regression
r p value β p value
Baseline characteristics




NYHA class 0.20 0.15
CMR parameters




0.30 <0.05 −0.10 0.6
Septal
thickness















0.38 <0.01 0.24 0.06
Resting LVOT
gradient
0.46 <0.001 0.29 0.03
NYHA indicates New York Heart Association; LVEDV, left ventricular end-
diastolic volume; LVEF, left ventricular ejection fraction; LGE, late gadolinium
enhancement; and LVOT, left ventricular outflow tract.
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Using a previously histologically-validated post-contrast
T1 mapping CMR technique [17], we demonstrated that
HCM patients have significantly shorter post-contrast
myocardial T1 times compared to healthy controls, con-
sistent with the presence of diffuse interstitial myocar-
dial fibrosis. Furthermore, the amount of this fibrosis
correlated with echocardiographic measures of LV filling
pressure, suggesting a mechanistic link between diffuse
fibrosis and abnormal diastolic function in HCM.
Previously, cardiac biopsy was the only means of com-
prehensively evaluating both regional and diffuse patterns
of myocardial fibrosis. However, invasive endomyocardial
biopsy is associated with significant procedural risks and
the ability to non-invasively image diffuse fibrosis in
patients with HCM would be a significant advance. Add-
itionally, biopsies obtained via this technique are mainly
derived from the right ventricular portion of the interven-
tricular septum and may not accurately reflect fibrotic
processes occurring in either the hypertrophied LV
septum or other ventricular segments.
Research utilizing CMR to assess myocardial fibrosis in
typical cohorts of HCM patients has previously only iden-
tified regional patterns of fibrosis with LGE sequences
[11-14,24]. This focus on LGE in HCM has led to
improved accuracy in the diagnosis of this condition in
patients with unexplained myocardial hypertrophy and
may enhance risk stratification for sudden death [25]. Not
all patients with HCM, however, exhibit LGE. Our study
detected diffuse myocardial fibrosis in HCM patients both
with and without LGE and there was no association
observed between the amount of LGE and post-contrast
myocardial T1 time. Additionally, post-contrast T1 times
of hypertrophied and non-hypertrophied myocardium did
not differ, reaffirming the histologically-proven [7] diffuse
nature of fibrosis in HCM. In contrast, the presence of
LGE correlates with segmental LV wall thickness [15,26].
These findings imply that diffuse and regional myocardial
fibrosis in HCM are distinct entities. The relative quan-
tities of these two types of fibrosis varied markedly be-
tween HCM patients in our study and may partially
account for the range of clinical manifestations in this
heterogeneous disease. There was a significant overlap in
post-contrast myocardial T1 times between HCM patients
and control subjects. Possible explanations for this in-
clude; variability in the fibrotic content in the myocar-
dium of healthy controls (including age-related changes);
subclinical myocardial disease; and the aforementioned
heterogeneity of the extent of diffuse myocardial fibrosis
in HCM.
The relationship between reduced post-contrast myo-
cardial T1 times and diastolic dysfunction has been
described in a group of patients with clinical heart fail-
ure [17]. Recently, in a cohort of heart failure patients
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between the amount of collagen type 1 found on endo-
myocardial biopsy and echocardiographic indices of dia-
stolic dysfunction [27]. Utilizing early mitral inflow to
early diastolic mitral annular velocity (E/e’) as a non-
invasive measure of increased LV filling pressure [28-31],
our study suggests a mechanistic link between higher LV
filling pressures in HCM patients and diffuse myocardial
fibrosis. Interestingly, we did not observe a significant
correlation between the amount of regional myocardial
fibrosis, as detected by LGE, and estimated LV filling
pressure.
Animal studies have demonstrated the anti-fibrotic
effects of medications that inhibit the angiotensin II
system [32]. Therefore, the ability to non-invasively
evaluate diffuse fibrosis in HCM is likely to enhance our
understanding of pathogenesis and disease progression
and may enable therapeutic trials of potential anti-
fibrotic agents. Furthermore, as it is uncertain as to
when the active pro-fibrotic state in the myocardium of
patients with HCM occurs, serial imaging using T1 map-
ping techniques over a patient’s lifetime may glean
crucial information about the timing of this process.
Study limitations
Our research has several limitations. Despite including
consecutive patients with asymmetric HCM referred to
our CMR centre, no patient experienced class III or IV
NYHA symptoms. Further studies involving patients
with more severe symptoms, whether due to intra-
cavitary obstruction and/or restrictive physiology, would
be required to demonstrate whether patients with a
greater disease burden might have even lower post-
contrast myocardial T1 times. Also, variations in the tim-
ing of image acquisition after contrast administration as
well as heart rate, hematocrit and renal function have
been proposed as potential confounders to the interpret-
ation of post-contrast T1 times [8]. Various T1 mapping
techniques have been designed to attempt to address
these issues, including an approach that utilized a con-
tinuous infusion of contrast to achieve equilibrium [20].
A T1 mapping technique to calculate the extracellular
volume (ECV) of the myocardium has also been
described [33]. Currently, no consensus exists on which
is the most accurate CMR T1 mapping method, with a
number of differing techniques demonstrating significant
correlations between post-contrast myocardial T1 time
and histologically-quantified fibrosis [17,20]. We
observed no significant differences in baseline values for
these putative confounding factors between our study
groups and, after statistical analysis, could not identify
any significant correlations with any of these factors and
post-contrast myocardial T1 times. In addition, post-
contrast blood pool T1 times were similar in bothgroups, strongly suggesting that the lower myocardial T1
times in HCM patients compared to controls were not
due to differences in contrast medium kinetics. Import-
antly, numerous studies have utilized a similar T1 map-
ping technique to that used in our study, and have
demonstrated shortened myocardial post-contrast T1
times in humans with a wide range of conditions known
to be associated with diffuse myocardial fibrosis, includ-
ing systolic heart failure [17], the diabetic heart [18,34],
chronic valvular heart disease [35] and remote myocar-
dial remodelling post-myocardial infarction [36]. Finally,
myocardial edema, identified by CMR, has been
described in some patients with HCM and may be due
to acute ischaemia [37]. Myocardial edema can affect T1
times [38], however, while its presence was not directly
assessed in this study, there was no clinical evidence of
recent acute myocardial pathology in any study patient.Conclusions
Using CMR post-contrast T1 mapping, this study has
demonstrated that patients with HCM have reduced
post-contrast myocardial T1 times, consistent with the
presence of diffuse interstitial fibrosis. Furthermore, the
independent association of post-contrast myocardial T1
time with estimated LV filling pressure (E/e’) suggests a
mechanistic link between altered myocardial compos-
ition and function. The non-invasive detection of diffuse
fibrosis, in combination with standard LGE sequences to
identify dense regional fibrosis, now allows a compre-
hensive evaluation of patterns of fibrosis in this condi-
tion. Further research utilizing this technique may
enhance our understanding of the relationships between
HCM genetic mutations, abnormal myocardial structure
and function, and risk stratification and may facilitate
the future development of disease-modifying therapies.
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